Molbio Diagnostics IPO is known for a potential 17% listing gain, as hinted by GMP, and the issue being booked nearly 5 times over. This information suggests a strong response to the IPO, with investors showing significant interest in the company’s shares.
The article from The Economic Times highlights the impressive booking of the issue, indicating a high demand for Molbio Diagnostics’ shares. This strong demand could lead to a higher listing gain, as hinted by GMP’s 17% prediction.
The Economic Times article does not provide information on whether the IPO is a good investment opportunity or whether investors should participate. It only reports on the potential listing gain and the strong booking of the issue.
The article’s focus is on the current market response to the Molbio Diagnostics IPO, providing a snapshot of the company’s shares and their potential listing gain.